Skip to content

Accrued Expenses at other companies

Delcath Systems logo
Delcath SystemsDCTH
$2.81M+51.0%
Iovance Biotherapeutics, Inc. logo
Iovance Biotherapeutics, Inc.IOVA
$88.07M+4.0%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$31.92M+41.2%
Immunome logo
ImmunomeIMNM
$21.88M+23.9%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$19M+11.8%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX

Other financials

Income statement

See full
Revenue$1.7M
Gross profit$1.3M
Operating income-$28.6M-283%
Net income-$26.6M-244%
EPS (diluted)-$0.27-145%

Balance sheet

See full
Cash & equivalents$2.6M+2,350,466%
Total equity$35.3M-1.0%
Total assets$100.7M+10.1%

Cash flow

See full
Operating cash flow-$3.8M-179%

Valuation

See full
Market cap$60.45M-74.7%

Returns & leverage

See full
Return on equity-119.9%+46.7pp
Current ratio0.5×+0.1×

Where this comes from

Reported directly by Citius Oncology, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrentAndNoncurrent.

The official record: Citius Oncology, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about Citius Oncology, Inc.'s accrued expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Citius Oncology, Inc.'s accrued expenses?
Citius Oncology, Inc. (CTOR) reported accrued expenses of $4.06M in Q1 2026.
How has Citius Oncology, Inc.'s accrued expenses changed year-over-year?
Citius Oncology, Inc.'s accrued expenses decreased by 53.4% year-over-year, from $8.72M to $4.06M.
What does accrued expenses mean?
Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.